Q&A: What the future holds for the biopharma supply chain
By Juan Guerra
The cold chain pharmaceutical market has experienced tremendous growth due, in part, to the increasing number of biopharmaceuticals and vaccines entering the pipeline. This influx of specialty pharmaceutical products, such as cell and gene therapies (CGT), offers tremendous promise for patients worldwide. However, these products also introduce unique logistical challenges and considerations.
In this Q&A, Juan Guerra discusses how the market for cold chain products has changed in recent years as the needs of biopharma companies evolves and what the future holds for pharma supply chain in Europe.
